Abbott India closes insider window. ICICI targets Abbott India stock at INR 32,210 later this year

Published on 10/20/2026 at 00:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ICICI Securities set an INR 32,210 target on August 13, 2026. Abbott India stock posted INR 4.29 billion profit in June 2026.

Abbott India disclosure and earnings

Abbott India closed its insider trading window on September 28, 2026, ahead of quarterly results.
ICICI Securities set an INR 32,210 target on August 13, 2026, after June-quarter revenue rose 4.30 percent.
June 2026 profit reached INR 4.29 billion, up 17.10 percent year over year.
Market capitalization stood at INR 550.5 billion as of October 19, 2026.

Abbott India, INE358A01014, Illustration mit AI erstellt.

Abbott India (INE358A01014) closed its insider trading window ahead of its September-quarter results, while ICICI Securities kept an INR 32,210 target on the stock. The disclosure dated September 28, 2026, gives investors a defined timetable for the next earnings catalyst, while the latest reported quarter showed revenue of INR 18.14 billion and profit of INR 4.29 billion.

Three dated signals for investors

On August 13, 2026, DSIJ reported that ICICI Securities retained its recommendation and set a target of INR 32,210. The same report placed June-quarter revenue at INR 18.14 billion, up 4.30 percent year over year, and profit at INR 4.29 billion, up 17.10 percent.

On September 7, 2026, Abbott India disclosed the resignation of its company secretary and compliance officer, with the change scheduled to take effect on October 28, 2026. On September 28, 2026, StockFin reported that the insider trading window would remain closed until two days after the second-quarter results.

What does the target imply?

ICICI Securities based its INR 32,210 target on 36 times estimated fiscal year 2028 earnings per share, according to DSIJ. The report also identified weaker performance from selected Novo Nordisk brands as a factor investors must weigh against stronger power-brand growth and a June-quarter EBITDA margin of 28.80 percent.

Upcoming dates set the rhythm

StockFin identified October 28, 2026, as the effective date for the company secretary change. A separate earnings calendar cited by TradingView lists November 5, 2026, as the next earnings date.

Valuation meets operating growth

Abbott India's June 2026 figures show a business with expanding profit faster than revenue, but the reported 4.30 percent sales growth was below the broker's cited market growth comparison. The combination leaves the next results important for testing whether the 17.10 percent profit increase can continue while the company manages product-level pressure.

Abbott India is listed on the NSE under ticker ABBOTINDIA and operates in healthcare pharmaceuticals. Its market capitalization was INR 550.5 billion as of October 19, 2026, while the latest reported June 2026 profit was INR 4.29 billion.